An EGFR-targeted chitosan NP was created to silence the Mad2 gene using small interfering RNAs (siRNAs) in patients with A549 cell line NSCLC (epithelial carcinoma derived from a 58-year-old male patient, known to be KRAS mutant and EGFR wild type). Here, EGFR is linked to non-small cell lung carcinoma.